drug development, in context

WE ARE DEDICATED TO DEVELOPING NOVEL MEDICINES TO TRANSFORM THE LIVES OF PATIENTS WITH HORMONE RECEPTOR POSITIVE CANCERS 

 
 
Home Banner.jpg
 
Biomarkers Icon

Focus On HR+ Cancers

Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers. 

Therapeutic Focus Icon

Apristor® For PR+ Cancers

Apristor is an investigational medicine for breast, ovarian, and endometrial cancers. These cancers are progesterone-dependent and Apristor functions by blocking the progesterone receptor.

latest news
Social media